Market revenue in 2023 | USD 84.2 million |
Market revenue in 2030 | USD 120.3 million |
Growth rate | 5.2% (CAGR from 2023 to 2030) |
Largest segment | Purity>98% |
Fastest growing segment | Purity>98% |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Purity>98%, Purity<98% |
Key market players worldwide | Merck KGaA, GSK PLC, Cipla Ltd DR, Novartis AG ADR, Sanofi SA, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Mallinckrodt PLC Ordinary Shares - New, Cayman Chemical, Tokyo Chemical Industry, APExBIO Technology, Wilshire Technologies, Biosynth |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crocin market will help companies and investors design strategic landscapes.
Purity>98% was the largest segment with a revenue share of 95.25% in 2023. Horizon Databook has segmented the Sweden crocin market based on purity>98%, purity<98% covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing surgical procedures in the country are boosting the demand for paracetamol drugs to manage postoperative pains. According to OECD data, in 2022, around 10,334 total knee replacement procedures, which require pain management medication, were performed in the country.
The increasing geriatric population is likely to further boost the number of surgical procedures in the country. According to World Bank data, in 2022, the country’s population aged 65 years & above was over 2.12 million, projected to surge over the forecast period.
The government is undertaking favorable initiatives to reduce the economic burden of headaches, migraines, and other healthcare conditions. The total annual cost of migraine is approximately USD 5,400 for those having less than 3 migraine days per month and more than USD 26,000 for those with 21 to 28 migraine days per month.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden crocin market , including forecasts for subscribers. This country databook contains high-level insights into Sweden crocin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account